Depression studies

A randomised, double-blind, parallel-group, active-controlled, flexible dose study evaluating the effects of Lu AA21004 versus agomelatine in adult patients suffering from major depressive disorder...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

United Kingdom, Belgium, Austria, + 9 others

Sponsor

H. Lundbeck A/S

A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone for the Treatment of Major Depressive Disorder with Mixed Features (Protocol No D1050304)

This study ended early.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

United Kingdom

Sponsor

Sunovion Pharmaceuticals Inc.

A Randomized, Double-blind, Multicenter, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants ...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

France, Bulgaria, Czechia, + 1 other

Sponsor

Janssen-Cilag International NV

A randomized, double-blind, parallel-group study of the safety and efficacy of RO4917523 versus placebo, as adjunctive therapy in patients with major depressive disorder with inadequate response to...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Germany

Sponsor

F. Hoffmann-La Roche Ltd

Randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder – the EMC trial.

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Germany

Sponsor

Department of Psychiatry and Psychotherapy, University of Mainz

The effect of agomelatine on CLOCK gene expression in patients with major depressive disorder and healthy controls: an exploratory study.

This study ended early.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Austria

Sponsor

Medizinische Universität Wien

A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in ...

Current recruitment status is unconfirmed.

This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.

Countries

United Kingdom, Belgium, Bulgaria, + 5 others

Sponsor

Janssen-Cilag International NV

A Double-blind, Randomized, Placebo-controlled, Multicentre, Relapse-prevention Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder

Current recruitment status is unconfirmed.

This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.

Countries

Bulgaria, Latvia, Poland, + 1 other

Sponsor

H. Lundbeck A/S

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of...

Current recruitment status is unconfirmed.

This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.

Countries

France, Czechia, Finland, + 4 others

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.

A Multicenter, 52-week, Open-label Study to Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder

This study isn't currently recruiting.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Bulgaria, Estonia, Finland, + 6 others

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder

This study isn't currently recruiting.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

France, United Kingdom, Germany, + 4 others

Sponsor

Takeda Global Research & Development Centre (Europe) Ltd.

Cognitive behavioural therapy (CBT) for treatment resistant depression (TRD).

This study isn't currently recruiting.

Countries

United Kingdom

Sponsor

Department of Health